Genomic Vision Announce the Pursuit of Its Partnership With Sanofi and the Successful Completion of Its First Milestone
13 Maggio 2021 - 7:03PM
Business Wire
Regulatory News:
Genomic Vision (the “Company” - FR0011799907 – GV), a
biotechnology company that develops tools and services dedicated to
the analysis and control of changes in the genome, today announces
that they have successfully completed work package one of a
three-part research agreement for the genetic characterization of
Sanofi cell banks.
In 2019 Genomic Vision started the first part of a partnership
with Sanofi Genzyme (the specialty care global business unit of
Sanofi), to characterize transformed cell lines for bio-production
and to compare proprietary molecular combing technology with other
laboratory methods
The results obtained in this first milestone, consolidate
Genomic Vision’s working hypothesis and paved the way to a better
understanding of the genetic characterization of transformed cell
lines.
Molecular combing with the FiberVision® product lines provide
single molecule visual output of transgene integration patterns
with high sensitivity and quantitative results, without
amplification bias.
This has the power to precisely monitor the quality of cell
lines and assess their stability throughout the manufacturing
process, an essential step in the development and production of
numerous biological products including viral particles, recombinant
therapeutic proteins, monoclonal antibodies as well as contributing
to vaccine production.
In parallel, Genomic Vision, among other industrial companies,
continues working with the NIST (National Institute of Standards
and Technology) consortium to develop quality control tools to be
used in genome editing based therapies.
Dominique Remy-Renou, CEO of Genomic Vision, added: “With
resolution, visualization and sensitivity being key requirements
for genetic stability and clonality testing, molecular combing is
poised to help create a new benchmark for bioproduction and cell
line manufacturing. We are satisfied to complete successfully this
first milestone and are confident for the next ongoing work. The
engagement with Sanofi Genzyme serves as a proof point in how
Genomic Vision can expand utility of molecular combing in high
growth markets.”
***
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products
and services dedicated to the analysis (structural and functional)
of genome modifications as well as to the quality and safety
control of these modifications, in particular in genome editing
technologies and biomanufacturing processes. Genomic Vision
proprietary tools, based on DNA combing technology and artificial
intelligence, provide robust quantitative measurements needed to
high confidence characterization of DNA alteration in the genome.
These tools are mainly used for monitoring DNA replication in
cancerous cell, for early cancer detection and the diagnosis of
genetic diseases. Genomic Vision, based near Paris in Bagneux, is a
public listed company listed in compartment C of Euronext’s
regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
***
Member of the CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the universal
registration document filed with the AMF on February 9, 2021 under
reference number R.21-002, available on the web site of Genomic
Vision (www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210513005852/en/
Genomic Vision Dominique Remy-Renou CEO Tel.: +33 1 49 08
07 51 investisseurs@genomicvision.com
Ulysse Communication Press Relations Bruno Arabian
Tel.: +33 1 42 68 29 70 barabian@ulysse-communication.com
NewCap Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu
Grafico Azioni Genomic Vision (EU:GV)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Genomic Vision (EU:GV)
Storico
Da Apr 2023 a Apr 2024